Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00555724 | Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors | PHASE1 | COMPLETED | 40 | — | — | Jan 1, 2008 | Jul 1, 2010 | Jan 9, 2017 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| BIIB022 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BIIB022 | DRUG | IV infusion once every three weeks until disease progression or unacceptable toxicity |
Inclusion Criteria: * Age 18 years or older at the time of informed consent * Relapsed or refractory solid tumors following standard therapy. * ECOG Performance Status 0 or 1. Exclusion Criteria: * History of insulin-dependent diabetes, type 2 diabetes, or hemoglobin A1c \>6% at screening. * Hist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |